Aptorum Group Limited (APM)Healthcare | Biotechnology | London, United Kingdom | NasdaqCM
0.89 USD
-0.01
(-1.611%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.89 Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:25 p.m. EDT
APM exhibits weak momentum with a downward trend in recent price history, and the short-term forecasting model predicts a negative price change. The stock is highly volatile and has a negative forward P/E, suggesting poor earnings outlook. Additionally, the stock has no dividend history, and the fundamentals are weak with negative return on assets and equity. The recent news highlights regulatory issues and a high risk profile, making it a poor investment for both short-term and long-term strategies. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.110945 |
| MSTL | 0.112452 |
| AutoARIMA | 0.153617 |
| AutoTheta | 0.157975 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 54% |
| H-stat | 0.79 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.96 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 25.049 |
| Market Cap | 7,211,297 |
| Forward P/E | -1.25 |
| Beta | -0.01 |
| Website | https://www.aptorumgroup.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.04651165 |
| Address1 | 17 Hanover Square |
| All Time High | 332.8 |
| All Time Low | 0.46 |
| Ask | 1.15 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 24,400 |
| Average Daily Volume3 Month | 61,285 |
| Average Volume | 61,285 |
| Average Volume10Days | 24,400 |
| Beta | -0.009 |
| Bid | 0.6097 |
| Bid Size | 2 |
| Book Value | 2.838 |
| City | London |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.8855 |
| Current Ratio | 0.782 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.95 |
| Day Low | 0.8731 |
| Debt To Equity | 25.049 |
| Display Name | Aptorum |
| Earnings Timestamp End | 1,746,043,200 |
| Earnings Timestamp Start | 1,746,043,200 |
| Ebitda | -1,562,482 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 1.388 |
| Enterprise Value | -2,169,279 |
| Eps Forward | -0.71 |
| Eps Trailing Twelve Months | -0.19 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.86028 |
| Fifty Day Average Change | 0.025220037 |
| Fifty Day Average Change Percent | 0.02931608 |
| Fifty Two Week Change Percent | 4.651165 |
| Fifty Two Week High | 4.47 |
| Fifty Two Week High Change | -3.5844998 |
| Fifty Two Week High Change Percent | -0.8019016 |
| Fifty Two Week Low | 0.65 |
| Fifty Two Week Low Change | 0.23550004 |
| Fifty Two Week Low Change Percent | 0.36230776 |
| Fifty Two Week Range | 0.65 - 4.47 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,545,143,400,000 |
| Float Shares | 4,458,707 |
| Forward Eps | -0.71 |
| Forward P E | -1.2471832 |
| Free Cashflow | -1,097,453 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16409999 |
| Held Percent Institutions | 0.02434 |
| Implied Shares Outstanding | 8,143,757 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,674,432,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. |
| Long Name | Aptorum Group Limited |
| Market | us_market |
| Market Cap | 7,211,297 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_254483578 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -1,363,270 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 7,329,380 |
| Open | 0.8731 |
| Operating Cashflow | -1,836,546 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 44 20 8092 9299 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 0.8855 |
| Post Market Time | 1,776,463,801 |
| Previous Close | 0.9 |
| Price Hint | 4 |
| Price To Book | 0.3120155 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.752 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.014499962 |
| Regular Market Change Percent | -1.611107 |
| Regular Market Day High | 0.95 |
| Regular Market Day Low | 0.8731 |
| Regular Market Day Range | 0.8731 - 0.95 |
| Regular Market Open | 0.8731 |
| Regular Market Previous Close | 0.9 |
| Regular Market Price | 0.8855 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 10,967 |
| Return On Assets | -0.06524 |
| Return On Equity | -0.10786 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 6,346,823 |
| Shares Percent Shares Out | 0.0015 |
| Shares Short | 12,292 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 11,553 |
| Short Name | Aptorum Group Limited |
| Short Percent Of Float | 0.0021 |
| Short Ratio | 0.14 |
| Source Interval | 15 |
| Symbol | APM |
| Total Cash | 3,452,891 |
| Total Cash Per Share | 0.424 |
| Total Debt | 3,442,928 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.19 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.32213 |
| Two Hundred Day Average Change | -0.43662995 |
| Two Hundred Day Average Change Percent | -0.33024737 |
| Type Disp | Equity |
| Volume | 10,967 |
| Website | https://www.aptorumgroup.com |
| Zip | W1S 1BN |